About Netbiz Dev

This author has not yet filled in any details.
So far Netbiz Dev has created 43 blog entries.

1- “Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of a lower-extremity joint provides a no inferior risk for the development of venous thromboembolism compared with current pharmacological protocols.”

A Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty C. Colwell, M. Froimson, M. Mont, M. Ritter, R. Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. The Journal of Bone and Joint Surgery, Feb 2014, 05;96(3):177-183 Multicenter study on 3060 patients finds ActiveCare® mobile compression device to be as effective as blood thinners [...]

2- “Our analysis shows that mobile, synchronized mechanical compression after major orthopedic surgery of the lower extremity is associated with significant cost savings of $369.5 per patient.”

Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty C. Colwell, M. Froimson, M. Mont, M. Ritter, R.Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. The Journal of Arthroplasty, September 2012; 27(8):1417-1584 Findings: Based on the SAFE study, this model was constructed to evaluate any difference in cost-effectiveness between ActiveCare+SFT® and Lovenox® [...]

3- “When compared with low-molecular-weight heparin, use of the mobile compression device for prophylaxis against venous thromboembolic events following total hip arthroplasty resulted in a significant decrease in major bleeding events.”

Thrombosis Prevention after Total Hip Arthroplasty. C. Colwell, M. Froimson, M. Mont, M. Ritter, R.Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. The Journal of Bone and Joint Surgery, March 2010; 92(3): 527-535 A Prospective Randomized Trial Comparing a Mobile Compression Device with Low Molecular Weight Heparin. See link to abstract Main results: Efficacy:  There [...]

4- “…We found a significantly lower prevalence of deep vein thrombosis with this combination than with the standard enoxaparin prophylaxis. This combined prophylaxis protocol has favorable risk-benefit and cost effectiveness profiles…”

DVT Prevention in Joint Arthroplasties: Continuous Enhanced Circulation Therapy vs. Low Molecular Weight Heparin. Y. Gelfer, H. Tavor, A. Or on, A. Peer, N. Halperin, D. Robinson. The Journal of Arthroplasty, February 2006; 21(2): 206-214 ActiveCare® treatment was at least 2 times more effective than enoxaparin in preventing DVT. Main results: Efficacy: The C.E.C.T protocol was [...]

February 2014

Activecare® gets professional recognition: Research on the device is published as a leading article in the most prestige journal JBJS. A special commentary is dedicated to this research in the Feb edition.  First Ever Large Scale Orthopedic Study Published in JBJS as Leading Article Approves the Change in How Patients are Treated to Prevent Deep Vein [...]

5- “…We found the evidence from this study convincing and the technological features of this novel device sufficient to support the selection of the CECT device for exclusive use at our institution. The CECT device used over our routine chemical agents significantly reduced the VTE events compared to the previous regimen of a fixed IPC device used with the same chemical agents…”

Venous Thromboembolic Disease Reduction with a Portable Pneumatic Compression Device. M. Froimson, T. Murray, A. Fazekas Journal of Arthroplasty February 2009; 24(2): 310-316 : Read more ActiveCare® + Enxoparin is more effective than IPC + Enxoparin. Main results: Efficacy: The replacement of the standard IPC by ActiveCare® reduced VTE rate from 3.6% to 1.3%. Length of Stay: The average [...]

6- “…significant reduction in rate of DVT after TKA when the CECT device was combined with LMWH…”

Portable Compression Device and LMWH Compared with LMWH for Thromboprophylaxis after Total Joint Arthroplasty. J. Edwards, P. Pulido, K. Ezzet, S. Copp, R. Walker,  C. Colwell Journal of Arthroplasty, December 2008; 23(8): 1122-1127: Read more ActiveCare® + Enoxaparin (vs Enoxaparin) - reduces DVT rates. Results: Efficacy: The addition of ActiveCare® to enoxaparin reduced the DVT rate from 12% [...]

December 2013

When an Israeli company nears the sales stage, the debate whether it is time to hire an American CEO almost always begins. A man who knows the target market, has more experience in sales (very few Israeli managers of life sciences companies have reached this stage), and who can open doors. A well-known American CEO [...]

October 2013

Dr. Robert Barrack in the Charnley Lecture at 2013 BOA Annual Congress: “It is the First Time That the US Deep Vein Thrombosis (DVT) Prevention Guidelines Have Been Modified for the Interest of the Orthopedic Surgeons.”

September 2013

You can now follow us on Twitter for the most recent updates on DVT prevention in orthopedic surgery. MCS presents a new video for orthopedic surgeons.